Open an account

Eagle Pharmaceuticals

EGRX · OTC

$0.885−$0.705 (−44.34%)TodayMarket closed ·
Prev close $1.59

About EGRX

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.

Employees
134
Headquarters
Woodcliff Lake, New Jersey
Listed
Feb 12, 2014
Sector
Health Care
Industry
Biotechnology
Website
eagleus.com

EGRX key statistics

Market cap
11.53M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.86K
Volume
578
Open price
$0.60
High today
$0.885
Low today
$0.60
52 Week high
$1.80
52 Week low
$0.0011

Eagle Pharmaceuticals (EGRX) at a glance

As of Oct 19, 2026, Eagle Pharmaceuticals (EGRX) shares are priced at $0.885, giving the company a market cap of 11.53M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.60 and $0.885. The current price is 47.5% above the day's low and 0.0% below its high.

Volume so far is 578 shares, below the average of 4.86K shares a day.

Over the past year Eagle Pharmaceuticals has ranged from $0.0011 to $1.80, and now sits 49% of the way up that range.

Eagle Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY23 it reported $1.18 per share against an estimate of $1.07.

EGRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 16.2% on average.

  1. Q3 FY21: reported $0.56 per share against an estimate of $0.85
  2. Q4 FY21: reported $0.85 per share against an estimate of $0.9588
  3. Q1 FY22: reported $4.04 per share against an estimate of $3.96
  4. Q2 FY22: reported $1.56 per share against an estimate of $3.43
  5. Q3 FY22: reported $1.12 per share against an estimate of $0.9248
  6. Q4 FY22: reported $1.10 per share against an estimate of $0.8466
  7. Q1 FY23: reported $1.26 per share against an estimate of $1.07
  8. Q2 FY23: reported $1.18 per share against an estimate of $1.07

EGRX news

  • Press releasePRNewswire

    Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

  • Avi Kapoor

    Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings

  • Avi Kapoor

    Dow Gains 100 Points; Joby Aviation Shares Spike Higher

  • Avi Kapoor

    US Stocks Edge Lower; Private Employment Beats Expectations

Similar companies

Companies in the same industry as Eagle Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.